S. Pandya

Two-dimensional phase I study of neratinib (NER) combined with temsirolimus (TEM) in patients (Pts) with solid tumors.

G. Shapiro, A. Berkenblit, J. Soria, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-in-HumanStudyofPF-05212384 ( PKI-587 ) , a Small-Molecule , Intravenous , Dual Inhibitor of PI 3 K and mTOR in Patients with Advanced Cancer

G. Shapiro, J. Tabernero, E. Kwak, 2015 .

Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced

G. Shapiro, E. Kwak, J. Bendell, 2015 .

A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies.

J. Baselga, G. Shapiro, E. Kwak, 2010 .

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer

G. Shapiro, J. Tabernero, E. Kwak, 2015, Clinical Cancer Research.

A phase 2 study of dalantercept, an activin receptor‐like kinase‐1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

A. Jimeno, A. Argiris, L. Wirth, 2016, Cancer.

Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors

Suzanne F. Jones, C. Rudin, G. Shapiro, 2019, Investigational New Drugs.

ACTR-46. AG-120, A FIRST-IN-class MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: UPDATED RESULTS FROM THE PHASE 1 NON-ENHANCING GLIOMA POPULATION

Raymond Y Huang, E. Maher, P. Wen, 2017 .

Abstract LB-89: Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study in patients with advanced solid tumors

M. Belvin, G. Shapiro, P. LoRusso, 2011 .